Carl Zeiss Meditec AG Deep Dive Q&A | Financial Outlook and Cost Reduction Plans

Carl Zeiss Meditec AG Deep Dive: Q&AFinancial and Strategic Outlook: Insights from Sebastian Frericks, Head of Investor Relations at Carl Zeiss Meditec AGUS Equipment Sales and Market DynamicsWhy Were US Equipment Sales, Especially in Microsurgery, Weak in Q3?Market Context: Weakness in microsurgery sales was driven by the late product cycle of older equipment and the launch of the new KINEVO 900 S neurosurgical platform in October 2024. Transition periods between product generations are typically slower.Financing Challenges: Private equity-backed clinics in the US, a significant customer segment, delayed investments due to high interest rates and expectations of an economic turnaround.Recovery Outlook: With the launch of KINEVO 900 S and early stabilization in order entries at the start of FY25, ZEISS anticipates returning to growth in the US market by 2025.Cost-Cutting Plans and Margin ImpactCan You Summarize Your Cost-Cutting Plans and Their Impact on Margin Goals?Background: R&D expenses peaked at 17% of sales in FY22 due to investments in digitalization, AI, and cloud-based infrastructure. These investments have built a robust ecosystem of integrated solutions.Optimization Strategy:Adjusted R&D prioritization by focusing on high-impact products.Implemented more responsive planning tools to align R&D investments with market conditions.Reduced or slowed down investments in areas with longer monetization timelines or less immediate commercial potential.Impact on Margins: These adjustments aim to improve productivity and preserve innovation while maintaining ZEISS’s leadership as the most R&D-intensive company in the ophthalmology industry.Bridging 2024 Guidance to 2025 ProfitabilityHow Do You Bridge 2024 Guidance to the Profitability Step-Up Expected in 2025E?Drivers of Recovery:-Full-year contribution from the DORC acquisition.-Recovery in the Chinese market from inventory destocking.-Continued cost efficiencies in R&D and sales operations.-Stabilized equipment sales and new product launches, including the KINEVO 900 S and QUATERA 700.Macro Conditions: While macroeconomic uncertainty persists, ZEISS expects a gradual improvement in consumer sentiment and demand across key markets.Profitability Targets: The company targets an EBIT margin recovery of 16-20%, depending on macroeconomic developments.R&D Strategy Under Cost Reduction PlanWhat Is Your R&D Strategy Under the Cost-Reduction Plan, and Where Will Savings Occur?Digital Investments: With foundational investments in cloud infrastructure complete, future spending will focus on developing applications and monetizable use cases.Integration of DORC: Streamlined development plans across cataract and retinal product lines, leveraging synergies from the DORC acquisition.Portfolio Focus: Narrowed the portfolio of premium IOLs to concentrate on high-potential products with the best commercial return.ConclusionWith a clear focus on profitability, innovation, and market recovery, Carl Zeiss Meditec AG is well-positioned for long-term growth. The company’s strategic initiatives, including the launch of advanced products like the KINEVO 900 S and optimized R&D investments, highlight its resilience and ability to adapt to evolving market dynamics.▶️ Other videos:Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/Company Presentation: https://seat11a.com/investor-relations-company-presentation/Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ESG Presentation: https://seat11a.com/investor-relations-esg/===============================T&CThis publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.